| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain Vol. 128 No. 1 © Guarantors of Brain 2005; all rights reserved
Scientific Commentary |
Sodium channel blockers and axonal protection in neuroinflammatory disease
| The first 10% of the full text of this article appears below. |
Although demyelination is a cardinal feature of neuroinflammatory conditions such as Guillain–Barré syndrome (GBS) and multiple sclerosis, axonal degeneration also occurs in these disorders. Because loss of axons causes permanent, non-remitting loss of neurological function, there is substantial interest in protection of axons in these situations. Protection of axons within white matter and peripheral nerves, however, is likely to require strategies different from those that might be expected to be protective in grey matter of the nervous system; the higher surface-to-volume ratio and different complement of molecules that are expressed in axons compared with neuronal cell bodies imply that the molecular mechanisms underlying axonal degeneration are different from those that cause
Department of Neurology and The Center for Neuroscience and Regeneration Research, Yale School of Medicine,New Haven, CT 06520, and Rehabilitation Research Center, VA Connecticut Healthcare, West Haven, CT 06516, USA
Correspondence to: Stephen G. Waxman, MD, PhD, Department of Neurology, LCI 707, Yale Medical School, 333 Cedar Street, PO Box 208018, New Haven, CT 06520-8018, USA E-mail: Stephen.Waxman@yale.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kaneko, J. Wang, M. Kaneko, G. Yiu, J. M. Hurrell, T. Chitnis, S. J. Khoury, and Z. He Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J. Neurosci., September 20, 2006; 26(38): 9794 - 9804. [Abstract] [Full Text] [PDF]
|
|